BioLineRx (BLRX) Short term Debt (2021 - 2025)

BioLineRx has reported Short term Debt over the past 5 years, most recently at $4.5 million for Q4 2025.

  • Quarterly results put Short term Debt at $4.5 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $4.5 million (changed 0.0% YoY), and the annual figure for FY2025 was $4.5 million, changed 0.0%.
  • Short term Debt for Q4 2025 was $4.5 million at BioLineRx, roughly flat from $4.5 million in the prior quarter.
  • Over the last five years, Short term Debt for BLRX hit a ceiling of $4.5 million in Q4 2024 and a floor of $1.5 million in Q4 2022.
  • Median Short term Debt over the past 5 years was $3.1 million (2023), compared with a mean of $3.3 million.
  • Biggest five-year swings in Short term Debt: crashed 44.07% in 2022 and later skyrocketed 103.96% in 2023.
  • BioLineRx's Short term Debt stood at $2.8 million in 2021, then tumbled by 44.07% to $1.5 million in 2022, then skyrocketed by 103.96% to $3.1 million in 2023, then soared by 42.42% to $4.5 million in 2024, then changed by 0.0% to $4.5 million in 2025.
  • The last three reported values for Short term Debt were $4.5 million (Q4 2025), $4.5 million (Q4 2024), and $3.1 million (Q4 2023) per Business Quant data.